FDA Guidance Details Process for Breakthrough Therapy Designation

The FDA issued a long-awaited guidance Tuesday outlining how pharma companies can receive a breakthrough therapy designation for a new drug, opening a door to faster approval. The designation, mandated in the FDA Safety and Innovation Act, is reserved for drugs that treat a serious, life-threatening condition.
Drug Industry Daily